Arab Israeli Conflict
Middle East News
Hi Tech News
Mylan rejected Teva's $41 billion bid earlier this week.
Acquisition would create leading company with potential to transform global market for generics.
Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.
"...Patients living with severe allergies should have a lower-cost option."
Home use is expected to begin, first in Israel, next year. Only after succeeding in Israel will it be exported.
By JUDY SIEGEL-ITZKOVICH
Mylan had unanimously rejected Tea’s bid to acquire it for roughly $41 billion earlier in the week.
By NIV ELIS,GLOBES
The media and television personality Dana Grotsky, who – with Guy Pines – cohosts Good Evening With Guy Pines.
By JERUSALEM POST STAFF
B "Teva Pharmaceutical's new generic version of the drug Syprine… will cost 28 times what Syprine cost in 2010. We have a crisis in drug prices in this country," Senator Bernie Sanders said.
By RAN DAGONI / GLOBES
The average price of each transaction fell by about 38%, but there was a slight 9% in the number of transactions this year, up to 131 M&A deals.
By MAX SCHINDLER
Outside the meeting, thousands of soon-to-be laid-off Teva employees demonstrated with their families.
A proposal was made that there should be an incentive to other firms in Jerusalem to absorb as many dismissed Teva employees as possible.
By PEGGY CIDOR
In the early years of the state, Teva raised money on the newly established Tel Aviv Stock Exchange.
By GREER FAY CASHMAN
Please insert a valid email address